Author

B. Garmezy

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Phase I/II Study of Bavdegalutamide, a Proteolysis-Targeting Chimera Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer.

PURPOSE This phase I/II study (which, to our knowledge, is the first such study in humans) evaluated the safety and efficacy of bavdegalutamide (ARV-110), a proteolysis-targeting chimera (PROTAC) androgen receptor (AR) degrader, in patients with metastatic castration-resistant prostate cancer (mCRPC). PATIENTS AND ME...

Xin Gao, B. Garmezy, J. Vuky et al. · Journal of Clinical Oncology · 0 citations

Open access Sep 2026

12 Farnesyl Transferase Inhibitor (FTI) Darlifarnib Combined with Cabozantinib in Renal Cell Carcinoma (RCC): Updated Phase 1a Results from FIT-001

Abstract Background VEGFR- and IO-targeted therapies for metastatic RCC have limitations that can lead to disease progression, highlighting the need for well-tolerated and effective combination strategies. VEGFR-TKI resistance occurs through multiple escape mechanisms, with the mTOR pathway playing a central role in su...

Adanma Ayanambakkam, Y. Zakharia, L. Rosen et al. · The Oncologist · 0 citations

Open access Sep 2026

22 Phase II Study of Cemiplimab ± Fianlimab Following SBRT for Oligometastatic Clear-Cell RCC (LAG-BOOST) (NCT07223541)

Abstract Background Oligometastatic clear-cell renal cell carcinoma (ccRCC) is a biologically distinct, often indolent state where metastasis-directed therapy, including metastasectomy or SBRT, provides durable local control and delays systemic therapy. Randomized prospective trial evidence demonstrates a survival bene...

Abhirami Das, S. Balkhi, A. Mitta et al. · The Oncologist · 0 citations